SeaSpine to Participate in the Canaccord Genuity Virtual Musculoskeletal Conference

Rhea-AI Summary

SeaSpine Holdings Corporation (NASDAQ: SPNE) will present at the Canaccord Genuity Virtual Musculoskeletal Conference on May 20, 2021, at 1:00 PM ET. The presentation will focus on their innovative surgical solutions for spinal disorders. A live and archived webcast will be accessible on the Investor Relations page of their website. SeaSpine specializes in orthobiologics and spinal implants, aiming to enhance bone fusion rates for various orthopedic surgeries. Their products are marketed in the U.S. and around 30 countries through exclusive distribution partners.

News Market Reaction – SPNE

-2.64%

-2.64% Session move

In the trading session that priced this news, SPNE declined 2.64%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the Company will present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021, beginning at 1:00 PM ET.

A live and archived webcast of the event will be available from the Investor Relations page of the Company's website at investor.seaspine.com.

About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Relations Contact
Leigh Salvo
(415) 937-5402
ir@seaspine.com

FAQ

When is SeaSpine's presentation at the Canaccord Genuity Virtual Musculoskeletal Conference?

SeaSpine will present on May 20, 2021, at 1:00 PM ET.

How can I watch SeaSpine's presentation live?

A live and archived webcast will be available on SeaSpine's Investor Relations page.

What is SeaSpine's focus in the medical technology sector?

SeaSpine focuses on surgical solutions for spinal disorders, including orthobiologics and spinal implants.

In how many countries does SeaSpine market its products?

SeaSpine markets its products in the U.S. and approximately 30 other countries.

What type of products does SeaSpine offer?

SeaSpine offers a range of surgical solutions including bone graft substitutes and spinal implants.